Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | PKLR | P30613 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.65 |
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803408 | 1.00 | PDE2A (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29368885 | 1.00 | PDE2A (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL16663940 | 0.92 | PDE2A (0.85) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29401241 | 0.89 | NPSR1 (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL4420540 | 0.89 | NPSR1 (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29369247 | 0.89 | NPSR1 (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL15423100 | 0.89 | PKLR (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29369342 | 0.89 | PKLR (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL15388144 | 0.88 | PDE2A (0.77) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL1315246 | 0.88 | PDE2A (0.77) | PDE2APKLRNPSR1RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504692-A | 3, 8-Dihydroxyl-6H-benzo [ c ] chromen-6-ketone 8-hydroxyl etherified derivatives of phosphodiesterase 2 inhibitor and application thereof | 常州大学 | 2025-02-25 | — | — | CN | claimed |
| WO-2024252410-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR ENHANCING ACTIVITY OF PINK1/PARKIN PATHWAY | Celagenex Research (India) Pvt. Ltd. (IN) | 2024-12-12 | — | — | WO | claimed |
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022040321-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4578500-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | Amazentis SA (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20250090479-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | IIera Derm LLC | 2025-03-20 | — | — | US | disclosed |
| EP-3369420-B1 | NON-THERAPEUTIC USE OF UROLITHIN A FOR IMPROVING COGNITIVE FUNCTION. | AMAZENTIS SA (CH) | 2025-03-12 | — | — | EP | disclosed |
| EP-3372228-B1 | NON-THERAPEUTIC METHOD OF INCREASING OR MAINTAINING MITOCHONDRIAL FUNCTION | AMAZENTIS SA (CH) | 2025-03-12 | — | — | EP | disclosed |
| CN-119504692-A | 3, 8-Dihydroxyl-6H-benzo [ c ] chromen-6-ketone 8-hydroxyl etherified derivatives of phosphodiesterase 2 inhibitor and application thereof | 常州大学 | 2025-02-25 | — | — | CN | disclosed |
| US-20250032565-A1 | METHOD AND COMPOSITION FOR PRODUCTION OF A PHYTONUTRIENT IN A MICROBIOME | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2025-01-30 | — | — | US | disclosed |
| WO-2024252410-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR ENHANCING ACTIVITY OF PINK1/PARKIN PATHWAY | Celagenex Research (India) Pvt. Ltd. (IN) | 2024-12-12 | — | — | WO | disclosed |
| CN-116774524-A | Photosensitive resin composition, method for producing pattern cured product, and use thereof | 武汉柔显科技股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4153306-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022229417-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Floratek Pharma SA (CH) | 2022-11-03 | — | — | WO | disclosed |
| US-20220233627-A1 | COMPOSITIONS COMPRISING PLANT EXTRACTS AND OILS AND RELATED METHODS OF TREATMENT AND THEIR PREPARATION | LE NADUR, LLC | 2022-07-28 | — | — | US | disclosed |
| CN-114732814-A | Application of urolithin A in preventing and treating allergic rhinitis and allergic asthma | 中山大学 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114423420-A | Methods and compositions for producing phytonutrients in microbiome | 捷通国际有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022040321-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090479-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | PDE2A 1915/4885PKLR 2812/4885NPSR1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.